Suven Life Sciences · NSE: SUVEN · BSE: 530239
Q2 FY26 results · Jul–Sep 2025
Suven Life Sciences reported revenue from operations of ₹0.92 crore (down 64.3% from Q2 FY25) and net loss of ₹77.31 crore for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 0.92 | 2.57 | −64.3% | 1.87 | −50.8% |
| Other income | 3.78 | 4.04 | −6.4% | 0.60 | +529.9% |
| Total income | 4.70 | 6.61 | −28.9% | 2.47 | +90.4% |
| Profit before tax | (77.31) | (49.64) | Loss widened | (51.52) | Loss widened |
| Net profit for the period | (77.31) | (49.64) | Loss widened | (51.52) | Loss widened |
| EPS, basic (₹) | (3.48) | (2.27) | Loss widened | (2.36) | Loss widened |
| Net margin (%) | -8410.6 | -1929.5 | -2759.8 |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 0.92 | 2.57 | −64.3% | 1.87 | −50.8% |
| Other income | 3.78 | 4.03 | −6.4% | 0.59 | +541.4% |
| Total income | 4.70 | 6.61 | −28.9% | 2.46 | +91.3% |
| Profit before tax | (15.45) | (11.07) | Loss widened | (14.78) | Loss widened |
| Net profit for the period | (15.45) | (11.07) | Loss widened | (14.78) | Loss widened |
| EPS, basic (₹) | (0.70) | (0.51) | Loss widened | (0.68) | Loss widened |
| Net margin (%) | -1680.3 | -430.3 | -791.7 |
Consolidated
- Filed with BSE
- 11 Nov 2025, 15:05 IST
- Board meeting
- 11 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 Nov 2025, 15:05 IST
- Board meeting
- 11 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE